文献速递泌尿生殖PETCTMR

18F-DCFPyL PET/CT检测高危局限性前列腺癌的前瞻性评估:与多参数MRI的比较

Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.
PubMed 文献 · AJR Am J Roentgenol · 2020-07-08

该前瞻性研究纳入26例高危局限性前列腺癌患者,分别行18F-DCFPyL PET/CT与多参数MRI(mpMRI)检查,并对可疑区域行靶向活检。结果显示两者基于病灶的敏感度和肿瘤检出率无显著差异,但PET/CT检出5个mpMRI未发现的真阳性肿瘤;肿瘤摄取显著高于非恶性组织,PSMA衍生的肿瘤负荷与疾病严重程度相关。

要点

  • 18F-DCFPyL PET/CT与mpMRI检测前列腺内肿瘤的敏感度分别为90.9%和86.4%(p=0.58),检出率分别为80%和88.4%(p=0.17)。
  • PET/CT检出5个mpMRI未发现的真阳性肿瘤。
  • 肿瘤最大SUV显著高于非恶性组织(p<0.05)。

关键影像表现/征象

  • 组织病理共识别44个肿瘤:Gleason分级(GG)1组1个、GG2组12个、GG3组7个、GG4组9个、GG5组15个。
  • 肿瘤最大SUV显著高于非恶性组织(p<0.05)。
  • 18F-DCFPyL PET/CT检出5个mpMRI未识别的真阳性肿瘤。

诊断标准与关键数值

  • 18F-DCFPyL PET/CT基于病灶的敏感度90.9%、肿瘤检出率80%;mpMRI敏感度86.4%、检出率88.4%(p=0.58/0.17)。
  • 总病灶PSMA与GG的关系:τ=0.27,p=0.08;PSMA肿瘤体积与GG的关系:τ=0.30,p=0.06。
  • PSMA肿瘤负荷密度与PSA密度中度相关(r=0.47,p=0.01)。

临床应用与阅片要点

  • 18F-DCFPyL PET/CT对前列腺内肿瘤敏感度高,可用于检出mpMRI未显示的可疑病灶。
  • 阅片时需结合PSMA摄取参数(SUV、PSMA肿瘤体积)评估肿瘤负荷,并与PSA密度关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to assess the utility of PET with (2S)-2-[[(1S)-1-carboxy-5-[(6-(18F)fluoranylpyridine-3-carbonyl)amino]pentyl]carbamoylamino]pentanedioic acid (18F-DCFPyL), a prostate-specific membrane antigen (PSMA)-targeted radiotracer, in the detection of high-risk localized prostate cancer as compared with multiparametric MRI (mpMRI). SUBJECTS AND METHODS. This HIPAA-compliant prospective study included 26 consecutive patients with localized high-risk prostate cancer (median age, 69.5 years [range, 53-81 years]; median prostate-specific antigen [PSA] level, 18.88 ng/mL [range, 1.03-20.00 ng/mL]) imaged with 18F-DCFPyL PET/CT and mpMRI. Images from PET/CT and mpMRI were evaluated separately, and suspicious areas underwent targeted biopsy. Lesion-based sensitivity and tumor detection rate were compared for PSMA PET and mpMRI. Standardized uptake value (SUV) and PSMA PET parameters were correlated with histopathology score, and uptake in tumor was compared with that in nonmalignant tissue. On a patient level, SUV and PSMA tumor volume were correlated with PSA density. RESULTS. Forty-four tumors (one in Gleason grade [GG] group 1, 12 in GG group 2, seven in GG group 3, nine in GG group 4, and 15 in GG group 5) were identified at histopathology. Sensitivity and tumor detection rate of 18F-DCFPyL PET/CT and mpMRI were similar (PET/CT, 90.9% and 80%; mpMRI, 86.4% and 88.4%; p = 0.58/0.17). Total lesion PSMA and PSMA tumor volume showed a relationship with GG (τ = 0.27 and p = 0.08, τ = 0.30 and p = 0.06, respectively). Maximum SUV in tumor was significantly higher than that in nonmalignant tissue (p < 0.05). Tumor burden density moderately correlated with PSA density (r = 0.47, p = 0.01). Five true-positive tumors identified on 18F-DCFPyL PET/CT were not identified on mpMRI. CONCLUSION. In patients with high-risk prostate cancer, 18F-DCFPyL PET/CT is highly sensitive in detecting intraprostatic tumors and can detect tumors missed on mpMRI. Measured uptake is significantly higher in tumor tissue, and PSMA-derived tumor burden is associated with severity of disease.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Gaur S, Mena E, Harmon SA, et al. Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. AJR Am J Roentgenol. 2020. PMID: 32755168. doi:10.2214/AJR.19.22042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。